Easter Island drug raises cognition throughout life span
Contact: Will Sansom, 210-567-2579
SAN ANTONIO (June 29, 2012) — Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest in Alzheimer’s disease. Texas scientists seeking a way to prevent this decline have reported exciting results with a drug that has Polynesian roots.
The researchers, appointed in the School of Medicine at The University of Texas Health Science Center at San Antonio, added rapamycin to the diet of healthy mice throughout the rodents’ life span. Rapamycin, a bacterial product first isolated from soil on Easter Island, enhanced learning and memory in young mice and improved these faculties in old mice, the study showed.
“We made the young ones learn, and remember what they learned, better than what is normal,” said Veronica Galvan, Ph.D., assistant professor of physiology at the Barshop Institute for Longevity and Aging Studies, part of the UT Health Science Center. “Among the older mice, the ones fed with a diet including rapamycin actually showed an improvement, negating the normal decline that you see in these functions with age.”
The drug also lowered anxiety and depressive-like behavior in the mice, Dr. Galvan said. Anxiety and depression are factors that impair human cognitive performance. Lead author Jonathan Halloran conducted scientifically reliable tests to accurately measure these cognitive components in the rodents.
Venturing into the open
Mice are burrowers that prefer tunnels with walls. To observe behavior, Halloran used an elevated maze of tunnels that led to a catwalk. “All of a sudden the mice are in open space,” Halloran said. “It’s pretty far from the floor for their size, sort of like if a person is hiking and suddenly the trail gets steep. It’s pretty far down and not so comfortable.”
Mice with less anxiety were more curious to explore the catwalk. “We observed that the mice fed with a diet containing rapamycin spent significantly more time out in the open arms of the catwalk than the animals fed with a regular diet,” Halloran said.
The second test measured depressive-like behavior in the rodents. Mice do not like to be held by their tails, which is the way they are moved from cage to cage. Inevitably they struggle to find a way out. “So we can measure how much and how often they struggle as a measure of the motivation they have to get out of an uncomfortable situation,” Dr. Galvan said.
Rapamycin acts like an antidepressant
Some mice barely struggle to get free, but if an antidepressant is administered they struggle a lot more. This behavior is very sensitive to the action of antidepressants and is a reliable measure of whether a drug is acting like an antidepressant, Dr. Galvan said.
“We found rapamycin acts like an antidepressant — it increases the time the mice are trying to get out of the situation,” she said. “They don’t give up; they struggle more.”
The reductions of anxiety and depressive-like behavior in rapamycin-treated mice held true for all ages tested, from 4 months of age (college age in human years) to 12 months old (the equivalent of middle age) to 25 months old (advanced age).
Feel-good chemicals elevated
The researchers measured levels of three “happy, feel-good” neurotransmitters: serotonin, dopamine and norepinephrine. All were significantly augmented in the midbrains of mice treated with rapamycin. “This is super-interesting, something we are going to pursue in the lab,” Dr. Galvan said.
Dr. Galvan and her team published research in 2010 showing that rapamycin rescues learning and memory in mice with Alzheimer’s-like deficits. The elevation of the three neurotransmitters, which are chemical messengers in the brain, may explain how rapamycin accomplished this, Dr. Galvan said.
Rapamycin is an antifungal agent administered to transplant patients to prevent organ rejection. The drug is named for Rapa Nui, the Polynesian title for Easter Island. This island, 2,000 miles from any population centers, is the famed site of nearly 900 mysterious monolithic statues.
This study became available online June 28 as a manuscript in press in the journal Neuroscience.
The University of Texas Health Science Center at San Antonio, one of the country’s leading health sciences universities, ranks in the top 3 percent of all institutions worldwide receiving federal funding. Research and other sponsored program activity totaled $231 million in fiscal year 2011. The university’s schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced approximately 26,000 graduates. The $736 million operating budget supports eight campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways “We make lives better®,” visit www.uthscsa.edu.
HOME [HSC NEWS]
| About UTHSCSA
| News Releases | Mission
Magazine | Grand Rounds Newly
Granted | Submit News | HSC
News Archive | Video Index